Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeuroDirect Ketamine single-ascending-dose topical study in healthy adults
ACTRN12623000061639Phase 2Not yet recruiting
- Sponsor
- Psycheceutical Bioscience
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing NeuroDirect Ketamine with Placebo (2 arms). Primary endpoint: Safety and tolerability of NeuroDirect Ketamine after a single topical dose. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
NeuroDirect Ketamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on ACTRN12623000061639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000061639.